Who
Howard Horn
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Ultragenyx Pharmaceutical; CFO, Vir Biotechnology.
In numbers
- Trades disclosed
- 55
- Buys
- 0
- Sells
- 23
- Bought
- $0
- Sold
- $7.6M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 10 Oct 2019
- Last trade
- 15 Oct 2026
- Last filed
- 19 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 19 Oct 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $108K7,066 at $15.27 | filing |
| 3 Aug 2026filed 4 Aug 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $117K4,696 at $24.92 | filing |
| 3 Aug 2026filed 4 Aug 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $117K4,696 at $24.92 | filing |
| 1 Jul 2026filed 6 Jul 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $156K4,698 at $33.13 | filing |
| 1 Jul 2026filed 6 Jul 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $156K4,698 at $33.13 | filing |
| 1 Jun 2026filed 1 Jun 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $111K4,653 at $23.77 | filing |
| 1 Jun 2026filed 1 Jun 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $111K4,653 at $23.77 | filing |
| 1 May 2026filed 4 May 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $117K4,683 at $24.90 | filing |
| 1 May 2026filed 4 May 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $117K4,683 at $24.90 | filing |
| 16 Apr 2026filed 20 Apr 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —34,674 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —59,952 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —59,952 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —34,674 at $0.00 | filing |
| 1 Apr 2026filed 2 Apr 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $98K4,683 at $20.97 | filing |
| 1 Apr 2026filed 2 Apr 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $98K4,683 at $20.97 | filing |
| 3 Mar 2026filed 3 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $37K1,635 at $22.40 | filing |
| 3 Mar 2026filed 3 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $37K1,635 at $22.40 | filing |
| 2 Mar 2026filed 3 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $121K5,290 at $22.80 | filing |
| 2 Mar 2026filed 3 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $70K3,119 at $22.54 | filing |
| 2 Mar 2026filed 3 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $121K5,290 at $22.80 | filing |
News
Rep. Gilbert Ray Cisneros, Jr. Buys Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)RARE · themarketsdaily.com · 15 Oct 2026Ultragenyx (NASDAQ: RARE) agrees to sell PRV for $203 million in cashRARE · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Howard Horn; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.